Clinical Application of Risdiplam in 5q Spinal Muscular Atrophy: A Narrative Review

Area of Science:

• Genetics and Molecular Biology
• Pharmacology and Therapeutics
• Neurology

Background:

• Spinal muscular atrophy (SMA) is a genetic disorder caused by mutations in the survival motor neuron (SMN) gene, resulting in reduced SMN protein levels.
• Low SMN protein levels lead to motor neuron degeneration and progressive muscle weakness, characteristic of SMA.
• Current therapeutic strategies aim to increase SMN protein levels to counteract disease progression.

Purpose of the Study:

• To review clinical trials and summarize data on Risdiplam for SMA treatment.
• To systematically evaluate the efficacy and safety profile of Risdiplam.
• To provide a comprehensive reference for Risdiplam's clinical application and future research directions.

Main Methods:

• Review of published and presented clinical trial data for Risdiplam in SMA patients.
• Systematic evaluation of efficacy endpoints, including motor function and SMN protein levels.
• Assessment of safety data, including adverse events and tolerability.

Main Results:

• Risdiplam demonstrated an increase in functional SMN protein (SMN-fl) production through modification of SMN2 gene splicing.
• Clinical data indicate positive effects on motor function and other relevant endpoints in SMA patients treated with Risdiplam.
• The safety profile of Risdiplam was evaluated, with common adverse events noted.

Conclusions:

• Risdiplam is an effective RNA splicing modifier for treating spinal muscular atrophy by enhancing SMN-fl protein levels.
• The drug shows a favorable efficacy and safety profile, supporting its role in SMA management.
• Further research and economic evaluations are warranted to optimize Risdiplam's clinical utility and compare it with other SMA therapies.